News
Stay up to date on the latest crypto trends with our expert, in-depth coverage.
1SEC crypto safe harbor heads to White House review, proposal due 'shortly' says Atkins2Nvidia CoWoS production capacity to reach 650,000 units in 2026, up 76% year-on-year; 840,000 units in 2027. Next-generation Rubin GPU mass production target lowered from 2 million to 1.5 million units due to HBM4 validation delays.3Geopolitical Pause or Rising Tensions? Markets Brace for Iran's Critical Deadline
General Catalyst pledges $5 billion investment in India across the next five years
101 finance·2026/02/20 06:57
All about Ethereum’s derivatives reset as exchange reserves hit multi-year lows
AMBCrypto·2026/02/20 06:33
Indonesia secures 19% tariff deal with US, palm oil and other commodities exempt
101 finance·2026/02/20 06:21
Gold edges lower as US dollar strengthens; focus shifts to upcoming inflation report
101 finance·2026/02/20 06:12
French Banking Giant Société Générale Launches Euro Stablecoin to XRPL Network
CoinEdition·2026/02/20 06:06
Taxbit Joins Backpack to Provide Compliant Crypto Tax Reporting
BlockchainReporter·2026/02/20 06:00
Here are all the reasons why a true altcoin season isn’t here yet
AMBCrypto·2026/02/20 05:03
Kelp’s rsETH Goes Live on Mantle, Unlocking DeFi Opportunities Across Aave and Merchant Moe
BlockchainReporter·2026/02/20 05:00
Flash
11:33
Alliance Global Partners recently announced the official initiation of research and coverage on HeYiBank Holdings, granting it a “Buy” rating for the first time.The institution has set a target price of $6.5 for Heyi Bank Holdings. This coverage marks that Heyi Bank Holdings has gained the attention and recognition of professional institutions. The "Buy" rating reflects analysts’ positive expectations for its future growth potential and stock price performance.
11:33
Climb Bio (stock code: CLYM) announced today that the U.S. Food and Drug Administration (FDA) has granted its candidate drug Budoprutug Fast Track designation for the treatment of primary membranous nephropathy.This designation will accelerate the review process for the drug, offering patients the possibility of earlier access to innovative therapies. Primary membranous nephropathy is an autoimmune kidney disease with limited treatment options. Fast Track designation aims to promote the development and review of drugs for serious diseases where medical needs have not been met. Climb Bio stated it will continue advancing the clinical development plan for Budoprotigide.
11:33
According to the latest revised agreement terms, AC Immune SA will receive a total upfront payment of 10 million Swiss francs.In addition, the company will also receive milestone payments related to the progress of the first phase of the project. This financial arrangement further strengthens the company’s cash flow and provides strong support for subsequent research and development activities.
News